

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use IMMIGOLIS INTRI safely and effectively. See full prescribing information for IMMIGOLIS INTRI.

IMMGOLIS INTRI™ (golimumab-sldi) injection, for intravenous use
Initial U.S. Approval: 2026

IMMGOLIS INTRI (golimumab-sldi) is a biosimilar* to SIMPONI ARIA (golimumab).

WARNING: SERIOUS INFECTIONS and MALIGNANCY *See full prescribing information for complete boxed warning.*

- Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving golimumab products (5.1).
- Discontinue IMMIGOLIS INTRI if a patient develops a serious infection or sepsis (5.1).
- Perform test for latent TB; if positive, start treatment for TB prior to starting IMMIGOLIS INTRI (5.1).
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1).
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which IMMIGOLIS INTRI is a member (5.2).

INDICATIONS AND USAGE

IMMGOLIS INTRI is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

- Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate (1.1)

DOSAGE AND ADMINISTRATION

- Adult patients with Rheumatoid Arthritis:
 - 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter (2.1)
- Dilution of supplied IMMIGOLIS INTRI solution with 0.9% Sodium Chloride Injection, USP is required prior to administration.

DOSAGE FORMS AND STRENGTHS

- Injection: 50 mg/4 mL (12.5 mg/mL) solution in a single-dose vial (3)

CONTRAINDICATIONS

- None (4)

WARNINGS AND PRECAUTIONS

- Serious Infections: Do not start IMMIGOLIS INTRI during an active

infection. If an infection develops, monitor carefully, and stop IMMIGOLIS INTRI if infection becomes serious (5.1).

- Invasive Fungal Infections: For patients who develop a systemic illness on IMMIGOLIS INTRI, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (5.1).
- Hepatitis B Reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop IMMIGOLIS INTRI and begin anti-viral therapy (5.1).
- Malignancies: More cases of lymphoma have been observed among patients receiving TNF blockers compared with patients in the control groups. Cases of other malignancies have been observed among patients receiving TNF blockers (5.2).
- Congestive Heart Failure: Worsening, or new onset, may occur. Stop IMMIGOLIS INTRI if new or worsening symptoms occur (5.3).
- Demyelinating Disorders: Exacerbation or new onset may occur (5.4).
- Lupus-like Syndrome: Discontinue IMMIGOLIS INTRI if symptoms develop (5.5).
- Hypersensitivity Reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (5.11).

ADVERSE REACTIONS

Most common adverse reactions (incidence $\geq 3\%$) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, and rash (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma, Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Biologics, including abatacept and anakinra: Increased risk of serious infections (5.1, 5.6, 5.7, 5.8, 7.2).
- Live vaccines should not be given with IMMIGOLIS INTRI (5.10, 7.3).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of IMMIGOLIS INTRI has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

Revised: 05/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS INFECTIONS and MALIGNANCY

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis (RA)

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults with Rheumatoid Arthritis

2.2 Evaluation for Tuberculosis and Hepatitis B Prior to Dosage

2.3 Important Administration Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

5.2 Malignancies

5.3 Congestive Heart Failure

5.4 Demyelinating Disorders

5.5 Autoimmunity

5.6 Use with Abatacept

5.7 Use with Anakinra

5.8 Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)

5.9 Hematologic Cytopenias

5.10 Vaccinations/Therapeutic Infectious Agents

5.11 Hypersensitivity Reactions

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Immunogenicity

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Methotrexate

7.2 Biologic Products for RA

7.3 Live Vaccines/Therapeutic Infectious Agents

7.4 Cytochrome P450 Substrates

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

16 HOW SUPPLIED/STORAGE AND HANDLING

Reference ID:

1

*Sections or subsections omitted from the full prescribing information are

FULL PRESCRIBING INFORMATION

WARNING: SERIOUS INFECTIONS and MALIGNANCY

SERIOUS INFECTIONS

Patients treated with golimumab products are at increased risk for developing serious infections that may lead to hospitalization or death [see *Warnings and Precautions (5.1)*]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IMMIGOLIS INTRI if a patient develops a serious infection.

Reported infections with TNF blockers, of which IMMIGOLIS INTRI is a member, include:

- Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before IMMIGOLIS INTRI use and during therapy. Initiate treatment for latent tuberculosis prior to IMMIGOLIS INTRI use.
- Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Consider the risks and benefits of treatment with IMMIGOLIS INTRI prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IMMIGOLIS INTRI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see *Warnings and Precautions (5.1)*].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, of which IMMIGOLIS INTRI is a member [see *Warnings and Precautions (5.2)*].

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis (RA)

IMMGOLIS INTRI, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults with Rheumatoid Arthritis

The IMMGOLIS INTRI dosage regimen is 2 mg per kg given as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter. Follow the dilution and administration instructions for IMMGOLIS INTRI [see *Dosage and Administration (2.4)*].

For patients with rheumatoid arthritis (RA), IMMGOLIS INTRI should be given in combination with methotrexate.

The efficacy and safety of switching between intravenous and subcutaneous formulations and routes of administration have not been established.

2.2 Evaluation for Tuberculosis and Hepatitis B Prior to Dosage

Prior to initiating IMMGOLIS INTRI and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see *Warnings and Precautions (5.1)*]. Prior to initiating IMMGOLIS INTRI, test patients for hepatitis B viral infection [see *Warnings and Precautions (5.1)*].

2.3 Important Administration Instructions

IMMGOLIS INTRI solution for intravenous infusion should be diluted by a healthcare professional using aseptic technique as follows:

1. Calculate the dosage and the number of IMMGOLIS INTRI vials needed based on the recommended adult dosage of 2 mg/kg and the patient's weight for RA. Each 4 mL vial of IMMGOLIS INTRI contains 50 mg of golimumab-sldi.
2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the solution in each vial is clear, colorless to light yellow. Do not use if opaque particles, discoloration, or other foreign particles are present.
3. Dilute the total volume of the IMMGOLIS INTRI solution with 0.9% Sodium Chloride Injection to a final volume of 100 mL. For example, this can be accomplished by withdrawing a volume of the 0.9% Sodium Chloride Injection from the 100-mL infusion bag or bottle equal to the total volume of IMMGOLIS INTRI. Slowly add the total volume of IMMGOLIS INTRI solution to the 100-mL infusion bag or bottle. Gently mix. Discard any unused solution remaining in the vials.
4. Prior to infusion, visually inspect the diluted IMMGOLIS INTRI solution for particulate matter or discoloration. Do not use if these are present.
5. Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.22 micrometer or less).
6. Do not infuse IMMGOLIS INTRI concomitantly in the same intravenous line with other agents. No physical biochemical compatibility studies have been conducted to evaluate the use of IMMGOLIS INTRI with other intravenous agents in the same intravenous line.
7. Infuse the diluted solution over 30 minutes.
8. Once diluted, the infusion solution can be stored for up to 4 hours at room temperature.

3 DOSAGE FORMS AND STRENGTHS

Injection: 50 mg/4 mL (12.5 mg/mL) clear, colorless to light yellow solution in a single-dose vial.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

Patients treated with golimumab products are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.

Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of IMMGOLIS INTRI and these biologic products is not recommended [*see Warnings and Precautions (5.6, 5.7) and Drug Interactions (7.2)*].

Treatment with IMMGOLIS INTRI should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of infection. Consider the risks and benefits of treatment prior to initiating IMMGOLIS INTRI in patients:

- with chronic or recurrent infection;
- who have been exposed to tuberculosis;
- with a history of an opportunistic infection;
- who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or
- with underlying conditions that may predispose them to infection.

Monitoring

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with IMMGOLIS INTRI. Discontinue IMMGOLIS INTRI if a patient develops a serious infection, an opportunistic infection, or sepsis. For patients who develop a new infection during treatment with IMMGOLIS INTRI, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy and closely monitor them.

Tuberculosis

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating IMMGOLIS INTRI and periodically during therapy.

Treatment of latent tuberculosis infection prior to therapy with TNF-blockers has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating IMMGOLIS INTRI, assess if treatment for latent tuberculosis is needed; An induration of 5 mm or greater is a positive tuberculin skin test, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Consider anti-tuberculosis therapy prior to initiation of IMMGOLIS INTRI in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Cases of active tuberculosis have occurred in patients treated with the subcutaneous formulation of golimumab products during and after treatment for latent tuberculosis. Monitor patients for the development of signs and symptoms of tuberculosis including patients who tested negative for latent tuberculosis infection prior to initiating therapy, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.

Consider tuberculosis in the differential diagnosis in patients who develop a new infection during IMMGOLIS INTRI treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Invasive Fungal Infections

If patients develop a serious systemic illness and they reside or travel in regions where mycoses are endemic, consider invasive fungal infection in the differential diagnosis. Consider appropriate empiric antifungal therapy and take into account both the risk for severe fungal infection and the risks of antifungal therapy while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections.

Hepatitis B Virus Reactivation

The use of TNF-blockers, of which IMMGOLIS INTRI is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive). In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients who received concomitant immunosuppressants.

All patients should be tested for HBV infection before initiating TNF-blocker therapy. For patients who test positive for hepatitis B surface antigen, consultation with a physician with expertise in the treatment of hepatitis B is recommended before initiating TNF-blocker therapy. The risks and benefits of treatment should be considered prior to prescribing TNF-blockers, including IMMGOLIS INTRI, to patients who are carriers of HBV. Adequate data are not available on whether antiviral therapy can reduce the risk of HBV reactivation in HBV carriers who are treated with TNF-blockers. Patients who are carriers of HBV and require treatment with TNF-blockers should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy.

In patients who develop HBV reactivation, TNF-blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming TNF-blockers after HBV reactivation has been controlled is not known. Therefore, prescribers should exercise caution when considering resumption of TNF-blockers in this situation and monitor patients closely.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use IMMIGOLIS INTRI safely and effectively. See full prescribing information for IMMIGOLIS INTRI.

IMMGOLIS INTRI™ (golimumab-sldi) injection, for intravenous use
Initial U.S. Approval: 2026

IMMGOLIS INTRI (golimumab-sldi) is a biosimilar* to SIMPONI ARIA (golimumab).

WARNING: SERIOUS INFECTIONS and MALIGNANCY *See full prescribing information for complete boxed warning.*

- Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving golimumab products (5.1).
- Discontinue IMMIGOLIS INTRI if a patient develops a serious infection or sepsis (5.1).
- Perform test for latent TB; if positive, start treatment for TB prior to starting IMMIGOLIS INTRI (5.1).
- Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1).
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which IMMIGOLIS INTRI is a member (5.2).

INDICATIONS AND USAGE

IMMGOLIS INTRI is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

- Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate (1.1)

DOSAGE AND ADMINISTRATION

- Adult patients with Rheumatoid Arthritis:
 - 2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter (2.1)
- Dilution of supplied IMMIGOLIS INTRI solution with 0.9% Sodium Chloride Injection, USP is required prior to administration.

DOSAGE FORMS AND STRENGTHS

- Injection: 50 mg/4 mL (12.5 mg/mL) solution in a single-dose vial (3)

CONTRAINDICATIONS

- None (4)

WARNINGS AND PRECAUTIONS

- Serious Infections: Do not start IMMIGOLIS INTRI during an active

infection. If an infection develops, monitor carefully, and stop IMMIGOLIS INTRI if infection becomes serious (5.1).

- Invasive Fungal Infections: For patients who develop a systemic illness on IMMIGOLIS INTRI, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (5.1).
- Hepatitis B Reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop IMMIGOLIS INTRI and begin anti-viral therapy (5.1).
- Malignancies: More cases of lymphoma have been observed among patients receiving TNF blockers compared with patients in the control groups. Cases of other malignancies have been observed among patients receiving TNF blockers (5.2).
- Congestive Heart Failure: Worsening, or new onset, may occur. Stop IMMIGOLIS INTRI if new or worsening symptoms occur (5.3).
- Demyelinating Disorders: Exacerbation or new onset may occur (5.4).
- Lupus-like Syndrome: Discontinue IMMIGOLIS INTRI if symptoms develop (5.5).
- Hypersensitivity Reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (5.11).

ADVERSE REACTIONS

Most common adverse reactions (incidence $\geq 3\%$) are: upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension, and rash (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma, Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Biologics, including abatacept and anakinra: Increased risk of serious infections (5.1, 5.6, 5.7, 5.8, 7.2).
- Live vaccines should not be given with IMMIGOLIS INTRI (5.10, 7.3).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of IMMIGOLIS INTRI has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.

Revised: 05/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SERIOUS INFECTIONS and MALIGNANCY

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis (RA)

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults with Rheumatoid Arthritis

2.2 Evaluation for Tuberculosis and Hepatitis B Prior to Dosage

2.3 Important Administration Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

5.2 Malignancies

5.3 Congestive Heart Failure

5.4 Demyelinating Disorders

5.5 Autoimmunity

5.6 Use with Abatacept

5.7 Use with Anakinra

5.8 Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)

5.9 Hematologic Cytopenias

5.10 Vaccinations/Therapeutic Infectious Agents

5.11 Hypersensitivity Reactions

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Immunogenicity

6.3 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Methotrexate

7.2 Biologic Products for RA

7.3 Live Vaccines/Therapeutic Infectious Agents

7.4 Cytochrome P450 Substrates

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

16 HOW SUPPLIED/STORAGE AND HANDLING

Reference ID:

*Sections or subsections omitted from the full prescribing information are

FULL PRESCRIBING INFORMATION

WARNING: SERIOUS INFECTIONS and MALIGNANCY

SERIOUS INFECTIONS

Patients treated with golimumab products are at increased risk for developing serious infections that may lead to hospitalization or death [see *Warnings and Precautions (5.1)*]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IMMIGOLIS INTRI if a patient develops a serious infection.

Reported infections with TNF blockers, of which IMMIGOLIS INTRI is a member, include:

- Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before IMMIGOLIS INTRI use and during therapy. Initiate treatment for latent tuberculosis prior to IMMIGOLIS INTRI use.
- Invasive fungal infections including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
- Bacterial, viral, and other infections due to opportunistic pathogens, including *Legionella* and *Listeria*.

Consider the risks and benefits of treatment with IMMIGOLIS INTRI prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IMMIGOLIS INTRI, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see *Warnings and Precautions (5.1)*].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, of which IMMIGOLIS INTRI is a member [see *Warnings and Precautions (5.2)*].

1 INDICATIONS AND USAGE

1.1 Rheumatoid Arthritis (RA)

IMMGOLIS INTRI, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults with Rheumatoid Arthritis

The IMMGOLIS INTRI dosage regimen is 2 mg per kg given as an intravenous infusion over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter. Follow the dilution and administration instructions for IMMGOLIS INTRI [see *Dosage and Administration (2.4)*].

For patients with rheumatoid arthritis (RA), IMMGOLIS INTRI should be given in combination with methotrexate.

The efficacy and safety of switching between intravenous and subcutaneous formulations and routes of administration have not been established.

2.2 Evaluation for Tuberculosis and Hepatitis B Prior to Dosage

Prior to initiating IMMGOLIS INTRI and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see *Warnings and Precautions (5.1)*]. Prior to initiating IMMGOLIS INTRI, test patients for hepatitis B viral infection [see *Warnings and Precautions (5.1)*].

2.3 Important Administration Instructions

IMMGOLIS INTRI solution for intravenous infusion should be diluted by a healthcare professional using aseptic technique as follows:

1. Calculate the dosage and the number of IMMGOLIS INTRI vials needed based on the recommended adult dosage of 2 mg/kg and the patient's weight for RA. Each 4 mL vial of IMMGOLIS INTRI contains 50 mg of golimumab-sldi.
2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the solution in each vial is clear, colorless to light yellow. Do not use if opaque particles, discoloration, or other foreign particles are present.
3. Dilute the total volume of the IMMGOLIS INTRI solution with 0.9% Sodium Chloride Injection to a final volume of 100 mL. For example, this can be accomplished by withdrawing a volume of the 0.9% Sodium Chloride Injection from the 100-mL infusion bag or bottle equal to the total volume of IMMGOLIS INTRI. Slowly add the total volume of IMMGOLIS INTRI solution to the 100-mL infusion bag or bottle. Gently mix. Discard any unused solution remaining in the vials.
4. Prior to infusion, visually inspect the diluted IMMGOLIS INTRI solution for particulate matter or discoloration. Do not use if these are present.
5. Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.22 micrometer or less).
6. Do not infuse IMMGOLIS INTRI concomitantly in the same intravenous line with other agents. No physical biochemical compatibility studies have been conducted to evaluate the use of IMMGOLIS INTRI with other intravenous agents in the same intravenous line.
7. Infuse the diluted solution over 30 minutes.
8. Once diluted, the infusion solution can be stored for up to 4 hours at room temperature.

3 DOSAGE FORMS AND STRENGTHS

Injection: 50 mg/4 mL (12.5 mg/mL) clear, colorless to light yellow solution in a single-dose vial.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Serious Infections

Patients treated with golimumab products are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.

Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of IMMGOLIS INTRI and these biologic products is not recommended [*see Warnings and Precautions (5.6, 5.7) and Drug Interactions (7.2)*].

Treatment with IMMGOLIS INTRI should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of infection. Consider the risks and benefits of treatment prior to initiating IMMGOLIS INTRI in patients:

- with chronic or recurrent infection;
- who have been exposed to tuberculosis;
- with a history of an opportunistic infection;
- who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or
- with underlying conditions that may predispose them to infection.

Monitoring

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with IMMGOLIS INTRI. Discontinue IMMGOLIS INTRI if a patient develops a serious infection, an opportunistic infection, or sepsis. For patients who develop a new infection during treatment with IMMGOLIS INTRI, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy and closely monitor them.

Tuberculosis

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent infection prior to initiating IMMGOLIS INTRI and periodically during therapy.

Treatment of latent tuberculosis infection prior to therapy with TNF-blockers has been shown to reduce the risk of tuberculosis reactivation during therapy. Prior to initiating IMMGOLIS INTRI, assess if treatment for latent tuberculosis is needed; An induration of 5 mm or greater is a positive tuberculin skin test, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Consider anti-tuberculosis therapy prior to initiation of IMMGOLIS INTRI in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.

Cases of active tuberculosis have occurred in patients treated with the subcutaneous formulation of golimumab products during and after treatment for latent tuberculosis. Monitor patients for the development of signs and symptoms of tuberculosis including patients who tested negative for latent tuberculosis infection prior to initiating therapy, patients who are on treatment for latent tuberculosis, or patients who were previously treated for tuberculosis infection.

Consider tuberculosis in the differential diagnosis in patients who develop a new infection during IMMGOLIS INTRI treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.

Invasive Fungal Infections

If patients develop a serious systemic illness and they reside or travel in regions where mycoses are endemic, consider invasive fungal infection in the differential diagnosis. Consider appropriate empiric antifungal therapy and take into account both the risk for severe fungal infection and the risks of antifungal therapy while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections.

Hepatitis B Virus Reactivation

The use of TNF-blockers, of which IMMGOLIS INTRI is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive). In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients who received concomitant immunosuppressants.

All patients should be tested for HBV infection before initiating TNF-blocker therapy. For patients who test positive for hepatitis B surface antigen, consultation with a physician with expertise in the treatment of hepatitis B is recommended before initiating TNF-blocker therapy. The risks and benefits of treatment should be considered prior to prescribing TNF-blockers, including IMMGOLIS INTRI, to patients who are carriers of HBV. Adequate data are not available on whether antiviral therapy can reduce the risk of HBV reactivation in HBV carriers who are treated with TNF-blockers. Patients who are carriers of HBV and require treatment with TNF-blockers should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy.

In patients who develop HBV reactivation, TNF-blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated. The safety of resuming TNF-blockers after HBV reactivation has been controlled is not known. Therefore, prescribers should exercise caution when considering resumption of TNF-blockers in this situation and monitor patients closely.

5.2 Malignancies

Malignancies in Pediatric Patients

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy ≤ 18 years of age), including golimumab products. Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF-blocker therapy. Most of the patients were receiving concomitant immunosuppressants. Most cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.

Malignancies in Adult Patients

The risks and benefits of TNF-blocker treatment including IMMGOLIS INTRI should be considered prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing a TNF-blocker in patients who develop a malignancy.

In the controlled portions of clinical trials of TNF-blockers including the subcutaneous formulation of golimumab more cases of lymphoma have been observed among patients receiving anti-TNF treatment compared with patients in the control groups. Patients with RA and other chronic inflammatory diseases, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy. Cases of acute and chronic leukemia have been reported with TNF-blocker use, including golimumab products, in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the general population for the development of leukemia.

Rare postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. Nearly all of the reported TNF-blocker associated cases have occurred in patients with Crohn's disease or ulcerative colitis. The majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine (AZA) or 6-mercaptopurine (6-MP) concomitantly with a TNF-blocker at or prior to diagnosis. A risk for the development for hepatosplenic T-cell lymphoma in patients treated with TNF-blockers cannot be excluded.

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocking agents, including golimumab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with chronic obstructive pulmonary disease [COPD], patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group. In an exploratory clinical trial evaluating the use of the subcutaneous formulation of golimumab in patients with severe persistent asthma, more patients treated with golimumab reported malignancies compared with control patients. The significance of this finding is unknown.

During the controlled portion of the Phase 3 trial in RA for golimumab, the incidence of malignancies other than lymphoma and NMSC per 100-patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the golimumab group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group.

5.3 Congestive Heart Failure

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including golimumab products. Some cases had a fatal outcome. In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality. Golimumab products have not been studied in patients with a history of CHF and IMMGOLIS INTRI should be used with caution in patients with CHF. If a decision is made to administer IMMGOLIS INTRI to patients with CHF, these patients should be closely monitored during therapy, and IMMGOLIS INTRI should be discontinued if new or worsening symptoms of CHF appear.

5.4 Demyelinating Disorders

Use of TNF-blockers, including golimumab products, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS), and peripheral demyelinating disorders, including Guillain-Barré syndrome. Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with golimumab products. Prescribers should exercise caution in considering the use of TNF-blockers, including IMMGOLIS INTRI, in patients with central or peripheral nervous system demyelinating disorders. Discontinuation of IMMGOLIS INTRI should be considered if these disorders develop.

5.5 Autoimmunity

Treatment with TNF blockers, including IMMGOLIS INTRI, may result in the formation of antinuclear antibodies (ANA). Rarely, treatment with TNF blockers, may result in the development of a lupus-like syndrome [see *Adverse Reactions (6.1)*]. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with IMMGOLIS INTRI, treatment should be discontinued.

5.6 Use with Abatacept

In controlled trials, the concurrent administration of another TNF-blocker and abatacept was associated with a greater proportion of serious infections than the use of a TNF-blocker alone; and the combination therapy, compared to the use of a TNF-blocker alone, has not demonstrated improved clinical benefit in the treatment of RA. Therefore, the combination of TNF-blockers, including IMMGOLIS INTRI, and abatacept is not recommended [see *Drug Interactions (7.2)*].

5.7 Use with Anakinra

Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocker was associated with a greater portion of serious infections and neutropenia and no additional benefits compared with the TNF-blocker alone. Therefore, the combination of anakinra with TNF-blockers, including IMMGOLIS INTRI, is not recommended [see *Drug Interactions (7.2)*].

5.8 Switching Between Biological Disease Modifying Antirheumatic Drugs (DMARDs)

Care should be taken when switching from one biologic product to another biologic product since overlapping biological activity may further increase the risk of infection.

5.9 Hematologic Cytopenias

There have been reports of pancytopenia, leukopenia, neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia in patients receiving golimumab. Caution should be exercised when using

TNF-blockers, including IMMGOLIS INTRI, in patients who have or have had significant cytopenias.

5.10 Vaccinations/Therapeutic Infectious Agents

Live Vaccines

Avoid live vaccines in patients treated with IMMGOLIS INTRI. In patients receiving anti-TNF therapy, limited data are available on the response to live vaccination, or on the secondary transmission of infection by live vaccines. Use of live vaccines could result in clinical infections, including disseminated infections.

Administration of live vaccines to infants exposed to IMMGOLIS INTRI *in utero* is not recommended for 6 months following the mother's last IMMGOLIS INTRI infusion during pregnancy [see *Drug Interactions (7.3)* and *Use in Specific Populations (8.1)*].

Whenever possible update immunizations prior to initiation of treatment with IMMGOLIS INTRI following current immunization guidelines for patients receiving immunosuppressive agents. Advise patients to discuss with the physician before seeking any immunizations.

Therapeutic Infectious Agents

Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with IMMGOLIS INTRI.

5.11 Hypersensitivity Reactions

In postmarketing experience, serious systemic hypersensitivity reactions (including anaphylaxis) have been reported following administration of the subcutaneous and intravenous formulations of golimumab products including IMMGOLIS INTRI. Hypersensitivity reactions including hives, pruritus, dyspnea, and nausea, were reported during infusion and generally within an hour after infusion. Some of these reactions occurred after the first administration of golimumab products. If an anaphylactic or other serious allergic reaction occurs, administration of IMMGOLIS INTRI should be discontinued immediately and appropriate therapy instituted.

6 ADVERSE REACTIONS

The most serious adverse reactions were:

- Serious Infections [see *Warnings and Precautions (5.1)*]
- Malignancies [see *Warnings and Precautions (5.2)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety data described below are based on one, randomized, double-blind, controlled Phase 3 trial in patients with RA receiving golimumab by intravenous infusion (Trial RA). The protocol included provisions for patients taking placebo to receive treatment with golimumab at Week 16 or Week 24 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment. Comparisons between placebo and golimumab were based on the first 24 weeks of exposure.

Trial RA included 197 control-treated patients and 463 golimumab-treated patients (which includes control-treated patients who switched to golimumab at Week 16). The proportion of patients who discontinued treatment due to adverse reactions in the controlled phase of Trial RA through Week 24 was 3.5% for golimumab-treated patients and 0.5% for placebo-treated patients. Upper respiratory tract infection was the most common adverse reaction reported in the trial through Week 24 occurring in 6.5% of golimumab-treated patients as compared with 7.6% of control-treated patients, respectively.

Infections

Serious infections observed in golimumab-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections. Cases of TB included pulmonary and extrapulmonary TB. The majority of the TB cases occurred in countries with a high incidence rate of TB [see *Warnings and Precautions* (5.1)].

In the controlled phase of Trial RA through Week 24, infections were observed in 27% of golimumab-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of golimumab-treated patients and 0.0% of control-treated patients. Through Week 24, the incidence of serious infections per 100 patient-years of follow-up was 2.2 (95% CI: 0.61, 5.71) for the golimumab group, and 0 (0.00, 3.79) for the placebo group. In the controlled and uncontrolled portions of Trial RA, 958 total patient-years of follow-up with a median follow-up of approximately 92 weeks, the incidence per 100 patient-years of all serious infections was 4.07 (95% CI: 2.90, 5.57) in patients receiving golimumab [see *Warnings and Precautions* (5.1)]. In the controlled and uncontrolled portions of Trial RA, in golimumab-treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).

Malignancies

One case of malignancy other than lymphoma and NMSC with golimumab was reported through Week 24 during the controlled phase of Trial RA. In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in golimumab-treated patients was 0.31 (95% CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).

Liver Enzyme Elevations

There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers.

In the controlled phase of Trial RA, through Week 24, ALT elevations $\geq 5 \times$ ULN occurred in 0.8% of golimumab-treated patients and 0% of control-treated patients and ALT elevations $\geq 3 \times$ ULN occurred in 2.3% of golimumab-treated patients and 2.5% of control-treated patients.

Since many of the patients in the Phase 3 trials were also taking medications that cause liver enzyme elevations (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs], MTX, or isoniazid prophylaxis), the relationship between golimumab and liver enzyme elevation is not clear.

Autoimmune Disorders and Autoantibodies

At Week 20 in Trial RA, 17% of golimumab-treated patients and 13% of control patients were newly antinuclear antibody (ANA)-positive. Of these patients, one golimumab-treated patient and no control-treated patients had newly positive anti-dsDNA antibodies [see *Warnings and Precautions* (5.5)].

Administration Reactions

In the controlled phase of Trial RA through Week 24, 1.1% of golimumab infusions were associated with an infusion reaction compared with 0.2% of infusions in the control group. The most common infusion reaction in golimumab-treated patients was rash. No serious infusion reactions were reported.

Other Adverse Reactions

[Table 1](#) summarizes the adverse drug reactions that occurred at a rate of at least 1% in the golimumab + MTX group with a higher incidence than in the placebo + MTX group during the controlled period of Trial RA through Week 24.

Table 1: Adverse Drug Reactions Reported by $\geq 1\%$ of Golimumab-Treated Patients and with a Higher Incidence than Placebo-Treated Patients in Trial RA through Week 24

	Placebo + MTX	Golimumab + MTX
Patients treated	197	463
Adverse Reaction		
Infections and infestations		
Upper respiratory tract infection (such as upper respiratory tract infection, nasopharyngitis, pharyngitis, laryngitis, and rhinitis)	12%	13%
Viral infections (such as influenza and herpes)	3%	4%
Bacterial infections	0%	1%
Bronchitis	1%	3%
Vascular disorders		
Hypertension	2%	3%
Skin and subcutaneous disorders		
Rash	1%	3%
General disorders and administration site conditions		
Pyrexia	1%	2%
Blood and lymphatic disorders		
Leukopenia	0%	1%

Other and Less Common Clinical Trial Adverse Drug Reactions

Adverse drug reactions that do not appear in [Table 1](#) or that occurred $< 1\%$ in golimumab-treated patients during Trial RA through Week 24 that do not appear in the Warnings and Precautions section included the following events listed by system organ class:

Infections and infestations: Superficial fungal infection, sinusitis, abscess, lower respiratory tract infection (pneumonia), pyelonephritis

Investigations: Alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, neutrophil count decreased

Nervous system disorders: Dizziness, paresthesia

Gastrointestinal disorders: Constipation

6.2 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other

studies, including those of golimumab or of other golimumab products.

Using an enzyme immunoassay (EIA) method, antibodies to golimumab were detected in 13 (3%) golimumab-treated patients following IV administration of golimumab in combination with MTX through Week 24 of Trial RA, of which all were neutralizing antibodies.

A drug-tolerant enzyme immunoassay (drug-tolerant EIA) method for detecting antibodies to golimumab was developed and validated. This method is approximately 16-fold more sensitive than the original EIA method with less interference from golimumab in serum. Through approximately 6 months, the incidence of antibodies to golimumab with the drug-tolerant EIA method for Trials RA, was 21%. Where tested, approximately one-third to one-half were neutralizing.

Patients with RA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab [see *Clinical Pharmacology* (12.3)].

6.3 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of golimumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to golimumab product exposure:

General Disorders and Administration Site Conditions: Infusion-related reactions [see *Warnings and Precautions* (5.11)]

Neoplasm benign and malignant: Melanoma, Merkel cell carcinoma [see *Warnings and Precautions* (5.2)]

Immune system disorders: Serious systemic hypersensitivity reactions (including anaphylactic reaction) [see *Warnings and Precautions* (5.11)], sarcoidosis

Respiratory, thoracic and mediastinal disorders: Interstitial lung disease

Skin and subcutaneous tissue disorders: Skin exfoliation, lichenoid reactions, bullous skin reactions

7 DRUG INTERACTIONS

7.1 Methotrexate

IMMGOLIS INTRI should be used with MTX for the treatment of RA [see *Clinical Studies* (14.1)]. Following IV administration, concomitant administration of methotrexate decreases the clearance of golimumab by approximately 9% based on population pharmacokinetics (PK) analysis. In addition, concomitant administration of methotrexate decreases the golimumab clearance by reducing the development of antibodies to golimumab.

7.2 Biologic Products for RA

An increased risk of serious infections has been seen in clinical RA studies of other TNF-blockers used in combination with anakinra or abatacept, with no added benefit; therefore, use of IMMGOLIS INTRI with other biologic products, including abatacept or anakinra, is not recommended [see *Warnings and Precautions* (5.6 and 5.7)]. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF-blocker. The concomitant use of IMMGOLIS INTRI with biologics approved to treat RA is not recommended because of the possibility of an increased risk of infection.

7.3 Live Vaccines/Therapeutic Infectious Agents

Live vaccines should not be given concurrently with IMMIGOLIS INTRI [see *Warnings and Precautions* (5.10)].

Therapeutic infectious agents should not be given concurrently with IMMIGOLIS INTRI [see *Warnings and Precautions* (5.10)].

Infants born to women treated with golimumab products during their pregnancy may be at increased risk of infection for up to 6 months. Administration of live vaccines to infants exposed to IMMIGOLIS INTRI *in utero* is not recommended for 6 months following the mother's last IMMIGOLIS INTRI infusion during pregnancy [see *Warnings and Precautions* (5.10), *Use in Specific Populations* (8.1)].

7.4 Cytochrome P450 Substrates

The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNF α) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of IMMIGOLIS INTRI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from postmarketing case reports with golimumab use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. An observational study of northern European births observed similar unadjusted rates of major birth defects in infants exposed *in utero* to golimumab compared to no treatment or nonbiologic systemic therapy. However, this study had important limitations (*see Data*).

Monoclonal antibodies, such as golimumab products, are transported across the placenta during the third trimester of pregnancy and may affect immune response in the *in utero* exposed infant. There are clinical considerations for the use of golimumab products in pregnant women [see *Clinical Considerations*]. In an animal reproductive study, golimumab administered by the subcutaneous route to pregnant monkeys, during the period of organogenesis, at doses that produced exposures approximately 200 times the maximum recommended human dose (MRHD) had no adverse fetal effects.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and of miscarriage is 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Golimumab products cross the placenta during pregnancy. Another TNF-blocking monoclonal antibody administered during pregnancy was detected for up to 6 months in the serum of infants. Consequently, these infants may be at increased risk of infection. Administration of live vaccines to

infants exposed to IMMGOLIS INTRI *in utero* is not recommended for 6 months following the mother's last IMMGOLIS INTRI infusion during pregnancy [see *Warnings and Precautions* (5.10) and *Drug Interactions* (7.3)].

Data

Human Data

An observational, exposure-based, cohort study based on data from the Swedish, Danish, and Finnish Medical Birth Registers conducted between 2006-2020 (Sweden and Denmark) and 2006-2019 (Finland) compared the risk of major birth defects in 134 live-born infants exposed to golimumab (116 from women treated for rheumatic conditions, 18 from women treated for ulcerative colitis) to no treatment or nonbiologic systemic therapy. The unadjusted rate of major birth defects in infants exposed in utero was similar across all groups. However, this study had important limitations such as a small number of pregnant women exposed to golimumab, a wide exposure ascertainment window, and incomplete risk adjustment for potential confounders.

Animal Data

In an embryofetal developmental toxicology study in which pregnant cynomolgus monkeys were treated with golimumab during the period of organogenesis from gestation days (GD) 20 to 51, exposures up to 200 times greater than the exposure at the MRHD (on an area under the curve (AUC) basis with maternal subcutaneous doses up to 50 mg/kg twice weekly) produced no evidence of fetal malformations or embryotoxicity. There was no evidence of maternal toxicity. Umbilical cord blood samples collected at the end of the second trimester showed that fetuses were exposed to golimumab during gestation.

In a pre- and postnatal developmental study in which pregnant cynomolgus monkeys were treated with golimumab from gestation day 50 to postpartum day 33, maximal drug concentrations up to 33 times greater than that found with the MRHD (on a maximum blood concentration ($C_{\max}$) basis at steady-state with maternal subcutaneous doses up to 50 mg/kg twice weekly) were not associated with any evidence of developmental defects in infants. There was no evidence of maternal toxicity. Golimumab was present in fetal serum at the end of the second trimester and in neonatal serum from the time of birth and for up to 6 months postpartum.

8.2 Lactation

Risk Summary

There is no information regarding the presence of golimumab products in human milk, the effects on breastfed infants, or the effects on milk production. Maternal IgG is known to be present in human milk. Golimumab is present in the milk of lactating cynomolgus monkeys (*see Data*). If golimumab products are transferred into human milk, the effects of local exposure in the gastrointestinal tract and potential limited systemic exposure in the infant to golimumab products are unknown. The developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for golimumab and any potential adverse effects on the breast-fed infants from IMMGOLIS INTRI, or from the underlying maternal condition.

Data

In the pre- and postnatal development study in cynomolgus monkeys in which golimumab was administered subcutaneously during pregnancy and lactation, golimumab was detected in the breast milk at concentrations that were approximately 400-fold lower than the maternal serum concentrations.

8.4 Pediatric Use

A pediatric assessment for IMMIGOLIS INTRI demonstrates that IMMIGOLIS INTRI is safe and effective for pediatric patients in an indication for which Simponi Aria® (golimumab) is approved. However, IMMIGOLIS INTRI is not approved for such indication due to marketing exclusivity for Simponi Aria (golimumab).

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with golimumab products and other TNF-blocking agents [see *Warnings and Precautions* (5.2)].

8.5 Geriatric Use

In Trial RA, the number of patients ages 65 or older was too small to make comparisons with younger golimumab-treated patients. Because there is a higher incidence of infections in the geriatric population in general, caution should be used in treating geriatric patients with IMMIGOLIS INTRI.

10 OVERDOSAGE

In a clinical study, 5 patients received single infusions of up to 1000 mg of golimumab without serious adverse reactions or other significant reactions.

11 DESCRIPTION

Golimumab-sldi is a human IgG1 κ monoclonal antibody specific for human tumor necrosis factor alpha (TNF α) that exhibits multiple glycoforms with molecular masses of approximately 150 to 151 kilodaltons. Golimumab-sldi was created using recombinant DNA technology, resulting in an antibody with human-derived antibody variable and constant regions. Golimumab-sldi is produced by a Chinese Hamster Ovary (CHO) cell line and is purified by a series of steps that includes measures to inactivate and remove viruses.

The IMMIGOLIS INTRI (golimumab-sldi) injection is a sterile solution of the golimumab-sldi antibody supplied in a 4-mL glass vial for intravenous infusion.

IMMIGOLIS INTRI is a preservative-free, clear, colorless to light yellow solution with a pH of approximately 5.5. IMMIGOLIS INTRI is not made with natural rubber latex. Each 4-mL vial of IMMIGOLIS INTRI contains 50 mg golimumab-sldi, histidine (1.60 mg), L-histidine monohydrochloride monohydrate (6.20 mg), polysorbate 80 (0.80 mg), trehalose (307.62 mg), and water for injection.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Golimumab products are human monoclonal antibodies that binds to both the soluble and transmembrane bioactive forms of human TNF α . This interaction prevents the binding of TNF α to its receptors, thereby inhibiting the biological activity of TNF α (a cytokine protein). There was no evidence of the golimumab product antibodies binding to other TNF superfamily ligands; in particular, the golimumab product antibodies did not bind or neutralize human lymphotoxin. Golimumab products did not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells.

Elevated TNF α levels in the blood, synovium, and joints have been implicated in the pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis. TNF α is an important mediator of the articular inflammation that is characteristic of these diseases. Golimumab

modulated the *in vitro* biological effects mediated by TNF in several bioassays, including the expression of adhesion proteins responsible for leukocyte infiltration (E-selectin, ICAM-1 and VCAM-1) and the secretion of proinflammatory cytokines (IL-6, IL-8, G-CSF and GM-CSF). The clinical relevance of these findings is unknown.

12.2 Pharmacodynamics

Following treatment with golimumab in patients with RA, decreases from baseline were observed in tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-3 (MMP-3), resistin, interleukin-6 (IL-6), macrophage inflammatory protein-1 (MIP-1b), vascular endothelial growth factor (VEGF), serum amyloid A (SAA), S100A12, and high sensitivity C-Reactive protein (hsCRP). Conversely, increases from baseline were observed in tartrate-resistant acid phosphatase (TRAP-5b). The clinical relevance of this information is not known.

12.3 Pharmacokinetics

Golimumab exhibited approximately dose-proportional pharmacokinetics in patients with RA over the dose range of 0.1 to 10.0 mg/kg following a single intravenous dose.

Absorption

Following a single intravenous administration of 2 mg/kg golimumab, a mean C_{max} of 44.4 ± 11.3 mcg/mL was observed in patients with RA. Data directly comparing 2 mg/kg intravenous administration and 50 mg subcutaneous administration are not available.

Distribution

Following a single intravenous administration of 2 mg/kg golimumab, the mean volume of distribution was estimated to be 115 ± 19 mL/kg in healthy subjects, and 151 ± 61 mL/kg in patients with RA. The volume of distribution of golimumab may indicate that golimumab is distributed primarily in the circulatory system with limited extravascular distribution.

Elimination

Following a single intravenous administration of 2 mg/kg golimumab, the systemic clearance of golimumab was estimated to be 6.9 ± 2.0 mL/day/kg in healthy subjects and 7.6 ± 2.0 mL/day/kg in patients with RA. The mean terminal half-life was estimated to be 12 ± 3 days in healthy subjects and the mean terminal half-life in RA patients was 14 ± 4 days.

Multiple Doses

When 2 mg/kg golimumab was administered intravenously to patients with RA at weeks 0, 4 and every 8 weeks thereafter, serum concentrations reached steady-state by Week 12. With concomitant use of MTX, treatment with 2 mg/kg golimumab every 8 weeks resulted in a mean steady-state trough serum concentration of approximately 0.4 ± 0.4 mcg/mL in patients with active RA.

Patients with RA who developed antibodies to golimumab generally had lower trough steady-state serum concentrations of golimumab [*see Adverse Reactions (6.2)*].

Specific Populations

No formal study of the effect of renal or hepatic impairment on the PK of golimumab products was conducted.

Body Weight

Following intravenous administration, patients with higher body weight tended to have slightly

higher serum golimumab concentrations than patients with lower body weights when golimumab was administered on a mg/kg (body weight) basis. However, based on population PK analysis, there were no clinically relevant differences in golimumab exposure following intravenous administration of 2 mg/kg golimumab in adult patients across a range of different body weights.

Drug Interaction Studies

Specific drug interaction studies have not been conducted with golimumab products.

Population PK analysis indicated that concomitant use of MTX, NSAIDs, oral corticosteroids, or sulfasalazine (SSZ) did not significantly influence the clearance of golimumab following IV administration.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term animal studies of golimumab products have not been conducted to evaluate its carcinogenic potential. Mutagenicity studies have not been conducted with golimumab products. A fertility study conducted in mice using an analogous anti-mouse TNF α antibody administered by the intravenous route at doses up to 40 mg/kg once per week showed no impairment of fertility.

14 CLINICAL STUDIES

14.1 Rheumatoid Arthritis

The efficacy and safety of golimumab were evaluated in one multicenter, randomized, double-blind, controlled trial (Trial RA, NCT00973479) in 592 patients $\geq$ 18 years of age with moderately to severely active RA despite concurrent MTX therapy and had not previously been treated with a biologic TNF-blocker. Patients were diagnosed according to the American College of Rheumatology (ACR) criteria, at least 3 months prior to administration of study agent and were required to have at least 6 swollen and 6 tender joints. Patients were randomized to receive either golimumab 2 mg/kg (N=395) or placebo (N=197) over a 30-minute intravenous infusion at Weeks 0, 4 and every 8 weeks thereafter in addition to their weekly maintenance MTX dose (15-25 mg). All patients receiving placebo + MTX received golimumab + MTX after Week 24, but the trial remained blinded until all patients had completed 108 weeks of treatment. Efficacy data were collected and analyzed through Week 52. Patients were allowed to continue stable doses of concomitant low dose corticosteroids (equivalent to $\leq$ 10 mg of prednisone a day) and/or NSAIDs. The use of other DMARDs including cytotoxic agents or other biologics was prohibited.

The primary endpoint in Trial RA was the percentage of patients achieving an ACR 20 response at Week 14. In Trial RA, the majority of subjects were women (82%) and were Caucasian (80%) with a median age of 52 years and a median weight of 70 kg. Median disease duration was 4.7 years, and 50% of the patients used at least one DMARD other than MTX in the past. At baseline, 81% of patients received concomitant NSAIDs and 81% of patients received low-dose corticosteroids (equivalent to $\leq$ 10 mg of prednisone a day). The median baseline DAS28-CRP was 5.9 and the median van der Heijde-Sharp score at baseline was 28.5.

Clinical Response


A greater percentage of patients treated with the combination of golimumab + MTX achieved ACR 20 at Week 14 and ACR 50 at Week 24 versus patients treated with the placebo + MTX as shown in [Table 2](#). The percent of patients achieving ACR 20 responses by visit for Trial RA is shown in [Figure 1](#).

Table 2: Trial RA – Proportion of Patients with an ACR Response

Trial RA Active RA, despite MTX			
	Placebo + MTX	Golimumab + MTX	95% CI ^a
N ^b	197	395	
ACR 20			
Week 14	25%	59%	25.9, 41.4
Week 24	32%	63%	23.3, 39.4
ACR 50			
Week 14	9%	30%	15.3, 27.2
Week 24	13%	35%	15.1, 28.4
ACR 70			
Week 14	3%	12%	5.3, 13.4
Week 24	4%	18%	8.8, 18.1

^a For difference in proportions.

^b N reflects randomized patients.

Figure 1: Trial RA – Percent of Patients Achieving ACR 20 Response Over Time: Randomized Patients

The analysis is based on the intent-to-treat population. Last observation carried forward was performed for missing data. Patients who discontinued treatment due to lack of efficacy were counted as non-responders, as were patients who started prohibited medication or failed to achieve at least a 10% improvement in joint counts at Week 16.

The improvement in all components of the ACR response criteria for the golimumab + MTX group was greater compared to the placebo + MTX group in Trial RA as shown in [Table 3](#).

Table 3: Trial RA — Components of ACR Response at Week 14

Trial RA Active RA, despite MTX		
	Placebo + MTX	Golimumab + MTX
N ^a	197	395
Number of swollen joints (0-66)		
Baseline	15	15
Week 14	11	6
Number of tender joints (0-68)		
Baseline	26	26
Week 14	20	13
Patient's assessment of pain (0-10)		
Baseline	6.5	6.5
Week 14	5.6	3.9
Patient's global assessment of disease activity (0-10)		
Baseline	6.5	6.5
Week 14	5.5	4.0
Physician's global assessment of disease activity (0-10)		
Baseline	6.3	6.2
Week 14	4.9	3.1
HAQ score (0-3)		
Baseline	1.6	1.6
Week 14	1.4	1.1
CRP (mg/dL) (0-1)		
Baseline	2.2	2.8
Week 14	1.8	0.9

Note: All values are means.

^a N reflects randomized patients; actual number of patients evaluable for each endpoint may vary.

At Week 14, a greater proportion of patients treated with golimumab + MTX achieved a low level of disease activity as measured by a DAS28-CRP less than 2.6 compared with the placebo + MTX group (15% compared to 5%; 95% CI for difference [6.3%, 15.5%]).

Radiographic Response

In Trial RA, structural joint damage was assessed radiographically and expressed as a change in van der Heijde-Modified Sharp Score (vdH-S) and its components, the erosion score and Joint Space Narrowing (JSN) score, at Week 24 compared to baseline. The golimumab + MTX treatment group inhibited the progression of structural damage compared with placebo + MTX, as assessed by total vdH-S score as shown in [Table 4](#).

Table 4: Trial RA – Radiographic Change From Baseline at Week 24

	Placebo + MTX (N=197)^a	Golimumab + MTX (N=395)^{a,b}
	Mean	Mean
Change Total vdH-S Score	1.1	0.03 [*]
Change Erosion Score	0.5	-0.1
Change JSN Score	0.6	0.1

^a N reflects randomized patients.

^b p-value is displayed only for the major secondary endpoint.

^{*} p≤0.001.

At Week 24, a greater proportion of patients in the golimumab + MTX group (71%) had no progression of structural damage (change in the total vdH-S score ≤ 0), compared to 57% of patients in the placebo + MTX group. At Week 52, the mean change from baseline in total vdH-S score was 1.2 in patients originally randomized to placebo + MTX who crossed over to golimumab + MTX at Week 16 or Week 24, and 0.1 in patients originally randomized to golimumab + MTX who remained on active treatment.

Physical Function Response in Patients with RA

Physical function was assessed by the disability index of the Health Assessment Questionnaire (HAQ-DI). At Week 14, the golimumab + MTX group showed greater mean improvement in the HAQ-DI compared with placebo + MTX (0.5 compared to 0.2; 95% CI for difference [0.2, 0.4]).

Other Health-Related Outcomes

General health status was assessed by the 36-item Short Form Health Survey (SF-36). In Trial RA, patients receiving golimumab + MTX demonstrated greater improvement from baseline compared with placebo + MTX in physical component summary (PCS), mental component summary (MCS) scores and in all 8 domains of the SF-36.

Fatigue was assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F) in Trial RA. Treatment with golimumab resulted in improvement in fatigue as measured by FACIT-F.

16 HOW SUPPLIED/STORAGE AND HANDLING

IMMGOLIS INTRI[®] (golimumab-sldi) injection is a clear, colorless to light yellow solution available in packs of 1 vial NDC 69448-029-64.

Vial

Each single-dose vial contains 50 mg of IMMGOLIS INTRI per 4 mL of solution.

Storage and Handling

Refrigerate IMMGOLIS INTRI at 36°F to 46°F (2°C to 8°C) and protect from light. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake.

If needed, IMMGOLIS INTRI may be stored at room temperature up to 77°F (25°C) for a maximum single period of 15 days in the original carton to protect from light. Once IMMGOLIS INTRI has been stored at room temperature, do not return the product to the refrigerator. If not used within 15 days at room temperature, discard IMMGOLIS INTRI.

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide).

Advise patients of the potential benefits and risks of IMMIGOLIS INTRI. Instruct patients to read the Medication Guide before starting IMMIGOLIS INTRI therapy and to read it each time the prescription is renewed.

Infections

Inform patients that IMMIGOLIS INTRI may lower the ability of their immune system to fight infections. Instruct the patient of the importance of contacting their doctor if they develop any symptoms of infection, including tuberculosis, invasive fungal infections, and hepatitis B reactivation.

Malignancies

Patients should be counseled about the risk of lymphoma and other malignancies while receiving IMMIGOLIS INTRI. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

Other Medical Conditions

Advise patients to report any signs of new or worsening medical conditions such as congestive heart failure, demyelinating disorders, autoimmune diseases, liver disease, cytopenias, or psoriasis.

Vaccinations

Inform patients that because IMMIGOLIS INTRI may lower the ability of their immune system to fight infections, they should avoid live vaccines. Inform pregnant patients receiving IMMIGOLIS INTRI that their infants should not receive live vaccines for 6 months following the last infusion of IMMIGOLIS INTRI during pregnancy. Advise patients and infants of women who received IMMIGOLIS INTRI during pregnancy to consult a physician before receiving any immunizations.



Manufactured by:
Accord BioPharma, Inc.
8041 Arco Corporate Drive,
Suite 200, Raleigh, NC 27617 USA
US License No. 2105

MEDICATION GUIDE
IMMGOLIS INTRI™ (im-goe-lis-in-tree)
(golimumab-sldi)
injection, for intravenous use

What is the most important information I should know about IMMGOLIS INTRI?

IMMGOLIS INTRI is a medicine that affects your immune system. IMMGOLIS INTRI can lower the ability of your immune system to fight infections. Some people have serious infections while receiving golimumab products, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that spread throughout their body. Some people have died from these serious infections.

- Your doctor should test you for TB and hepatitis B before starting BRANDNAME.
- Your doctor should monitor you closely for signs and symptoms of TB during treatment with IMMGOLIS INTRI. You should not start receiving IMMGOLIS INTRI if you have any kind of infection unless your doctor tells you to.

Before receiving IMMGOLIS INTRI, tell your doctor if you:

- think you have an infection or have symptoms of an infection such as:
 - fever, sweat, or chills
 - muscle aches
 - cough
 - shortness of breath
 - blood in phlegm
 - weight loss
 - warm, red, or painful skin or sores on your body
 - diarrhea or stomach pain
 - burning when you urinate or urinate more often than normal
 - feel very tired
- are being treated for an infection.
- get a lot of infections or have infections that keep coming back.
- have diabetes, HIV, or a weak immune system. People with these conditions have a higher chance for infections.
- have TB, or have been in close contact with someone with TB.
- live, have lived, or traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, blastomycosis). These infections may happen or become more severe if you use IMMGOLIS INTRI. Ask your doctor if you do not know if you have lived in an area where these infections are common.
- have or have had hepatitis B.
- use the medicine ORENCIA (abatacept), KINERET (anakinra), ACTEMRA (tocilizumab) or RITUXAN (rituximab).

After receiving IMMGOLIS INTRI, call your doctor right away if you have any symptoms of an infection. IMMGOLIS INTRI can make you more likely to get infections or make worse any infection that you have.

Cancer

- For children and adults receiving Tumor Necrosis Factor (TNF)-blocker medicines, including IMMGOLIS INTRI, the chances of getting cancer may increase.
- There have been cases of unusual cancers in children and teenage patients receiving TNF-blocking agents.
- People with inflammatory diseases, including rheumatoid arthritis (RA), especially those with very active disease, may be more likely to get lymphoma.
- Some people receiving TNF-blockers, like IMMGOLIS INTRI, developed a rare type of cancer called hepatosplenic T- cell lymphoma. This type of cancer often results in death. Most of these people were male teenagers or young men. Also, most people were being treated for Crohn's disease or ulcerative colitis with a TNF blocker and another medicine called azathioprine or 6-mercaptopurine, (6-MP).
- Some people treated with golimumab products developed skin cancer. If any changes in the appearance of your skin or growths on your skin occur during or after your treatment with IMMGOLIS INTRI, tell your doctor.
- You should see your doctor periodically for skin examinations, especially if you have a history of skin cancer.

What is IMMGOLIS INTRI?

IMMGOLIS INTRI is a prescription medicine called a TNF-blocker. IMMGOLIS INTRI is used to treat:

- adults with the medicine methotrexate (MTX) to treat moderately to severely active RA.

What should I tell my doctor before starting treatment with IMMGOLIS INTRI?

See “**What is the most important information I should know about IMMGOLIS INTRI?**”.

Before starting IMMGOLIS INTRI, tell your doctor about all your medical conditions, including if you:

- have an infection.
- have or have had lymphoma or any other type of cancer.
- have or have had heart failure.
- have or have had a condition that affects your nervous system, such as multiple sclerosis or Guillain-Barré syndrome.
- have a skin problem called psoriasis.
- have recently received or are scheduled to receive a vaccine. People receiving IMMGOLIS INTRI should not receive live vaccines or treatment with a weakened bacteria (such as BCG for bladder cancer). People receiving IMMGOLIS INTRI can receive non-live vaccines.
- have a baby and you were receiving IMMGOLIS INTRI during your pregnancy. Tell your baby’s doctor before your baby receives any vaccine. Your baby may have an increased chance of getting an infection for up to 6 months after birth.
- are pregnant or plan to become pregnant. It is not known if IMMGOLIS INTRI will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if IMMGOLIS INTRI passes into your breast milk. You and your doctor should decide if you will receive IMMGOLIS INTRI or breastfeed.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially, tell your doctor if you:

- use ORENCIA (abatacept) or KINERET (anakinra). You should not receive IMMGOLIS INTRI while you are also receiving ORENCIA (abatacept) or KINERET (anakinra).
- use other TNF-blocker medicines, including REMICADE (infliximab), HUMIRA (adalimumab), ENBREL (etanercept), or CIMZIA (certolizumab pegol).
- receive RITUXAN (rituximab) or ACTEMRA (tocilizumab).

Ask your doctor or pharmacist for a list of these medicines if you are not sure.

Keep a list of all your medicines with you to show your doctor and pharmacist each time you get a new medicine.

How should I receive IMMGOLIS INTRI?

- IMMGOLIS INTRI is prepared and given by a healthcare provider through a needle placed in your vein (infusion). The infusion is usually given in your arm and should take 30 minutes.
- Your doctor will decide how much IMMGOLIS INTRI you will receive. Your usual schedule for receiving IMMGOLIS INTRI after your first treatment should be:
 - 4 weeks after your first treatment
 - every 8 weeks after that
- If you miss an appointment to receive IMMGOLIS INTRI, make another appointment as soon as possible.

What are the possible side effects of IMMGOLIS INTRI?

IMMGOLIS INTRI can cause serious side effects, including:

See “**What is the most important information I should know about IMMGOLIS INTRI?**”

Serious Infections.

- Some patients have an increased chance of getting serious infections while receiving IMMGOLIS INTRI. These serious infections include TB and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients die from these infections. If you get an infection while receiving treatment with IMMGOLIS INTRI your doctor will treat your infection and may need to stop your IMMGOLIS INTRI treatment. Tell your doctor right away if you have any of the following signs of an infection while receiving or after receiving IMMGOLIS INTRI:
 - a fever
 - feel very tired
 - have a cough
 - have flu-like symptoms
 - warm, red, or painful skin
- Your doctor will examine you for TB and perform a test to see if you have TB. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with IMMGOLIS INTRI and during

treatment with IMMIGOLIS INTRI. Even if your TB test is negative your doctor should carefully monitor you for TB infections while you are receiving IMMIGOLIS INTRI. People who had a negative TB skin test before receiving golimumab products have developed active TB. Tell your doctor if you have any of the following symptoms while receiving or after receiving IMMIGOLIS INTRI:

- cough that does not go away
- low grade fever
- weight loss
- loss of body fat and muscle (wasting)

Hepatitis B infection in people who carry the virus in their blood. If you are a carrier of the hepatitis B virus (a virus that affects the liver), the virus can become active while you use IMMIGOLIS INTRI. Your doctor should do blood tests before you start treatment with IMMIGOLIS INTRI and while you are receiving IMMIGOLIS INTRI.

- Tell your doctor if you have any of the following symptoms of a possible hepatitis B infection:
 - feel very tired
 - dark urine
 - skin or eyes look yellow
 - little or no appetite
 - vomiting
 - muscle aches
 - clay-colored bowel movements
 - fevers
 - chills
 - stomach discomfort
 - skin rash

Heart failure, including new heart failure or worsening of heart failure that you already have can happen in people who use TNF-blocker medicines, including IMMIGOLIS INTRI. If you develop new or worsening heart failure with IMMIGOLIS INTRI, you may need to be treated in a hospital, and it may result in death.

- If you have heart failure before starting IMMIGOLIS INTRI, your condition should be watched closely during treatment with IMMIGOLIS INTRI.
- Call your doctor right away if you get new or worsening symptoms of heart failure during treatment with IMMIGOLIS INTRI (such as shortness of breath or swelling of your lower legs or feet, or sudden weight gain).

Nervous System Problems. Rarely, people receiving TNF-blocker medicines, including IMMIGOLIS INTRI, have nervous system problems such as multiple sclerosis or Guillain-Barré syndrome. Tell your doctor right away if you get any of these symptoms:

- vision changes
- weakness in your arms or legs
- numbness or tingling in any part of your body

Immune System Problems. Rarely, people receiving TNF-blocker medicines have developed symptoms that are like the symptoms of lupus. Tell your doctor if you have any of these symptoms:

- a rash on your cheeks or other parts of the body
- sensitivity to the sun
- new joint or muscle pains
- becoming very tired
- chest pain or shortness of breath
- swelling of the feet, ankles, or legs

Liver Problems. Liver problems can happen in people who receive TNF-blocker medicines, including IMMIGOLIS INTRI. These problems can lead to liver failure and death. Call your doctor right away if you have any of these symptoms:

- feel very tired
- skin or eyes look yellow
- poor appetite or vomiting
- pain on the right side of your stomach (abdomen)

Blood Problems. Low blood counts have been seen with golimumab products. Your body may not make enough blood cells that help fight infections or help stop bleeding. Symptoms include fever, bruising or bleeding easily, or looking pale. Your doctor will check your blood counts before and during treatment with IMMIGOLIS INTRI.

Allergic Reactions. Allergic reactions can happen in people who receive TNF-blocker medicines, including IMMIGOLIS INTRI. Some reactions may be serious and can be life-threatening. Some of these reactions can happen after receiving your first dose of IMMIGOLIS INTRI. Call your doctor right away if you have any of these symptoms of an allergic reaction:

- hives
- swollen face
- breathing trouble
- chest pain

The most common side effects of IMMIGOLIS INTRI include:

- upper respiratory infection (runny nose, sore throat, and hoarseness or laryngitis)
- abnormal liver tests
- decreased blood cells that fight infection
- viral infections, such as flu and cold sores in the mouth
- bronchitis

- high blood pressure
- rash

These are not all of the possible side effects of IMMIGOLIS INTRI.

Tell your doctor about any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMMIGOLIS INTRI.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your doctor or pharmacist for information about IMMIGOLIS INTRI that is written for health professionals.

What are the ingredients in IMMIGOLIS INTRI?

Active ingredient: golimumab-sldi.

Inactive ingredients: histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, trehalose, and water for injection. IMMIGOLIS INTRI is preservative-free and is not made with natural rubber latex.

Manufactured by: Accord BioPharma, Inc. 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617 USA

US License No. 2105

For more information go to www.immgolisintri.com.com or call 1-866-941-7875.

This Medication Guide has been approved by the U.S. Food and Drug Administration

Issued: 05/2026